Chaperonin-containing tailless complex polypeptide 1 subunit 6A negatively regulates autophagy and protects colorectal cancer cells from cisplatin-induced cytotoxicity

Figure 7 Inhibition of autophagy enhances the cytotoxicity of cisplatin. A-D: The MTS assay was conducted to assess the cell viability after applying the specified treatments for 24 hours (3-Methyladenine [3-MA]: 2 mM) (A and C), colony growth assay was performed with indicated treatments (cisplatin [DDP]: 1 μM; chloroquine diphosphate salt [CQ]: 5 μM; 3-MA: 0.5 mmol/L) (scale bar = 1 cm) (B and D); E: Following appropriate treatments for 24 hours, cell lysates were performed immunoblotting with indicated antibodies; F: Co-immunoblotting assay was conducted with the receptor-interacting protein kinase 3 antibody, and then subjected to immunoblotting; G: Schematic model of chaperonin-containing tailless complex polypeptide 1 subunit 6a (CCT6A) modulates the cytotoxicity of DDP via regulating autophagy. ^bP < 0.01 vs control (Ctrl). Bcl-xL: B-cell lymphoma-extra large; IgG: Immunoglobulin G (negative control antibody); MLKL: Mixed lineage kinase domain-like; Nec-1; Necrostatin-1; PARP-1; Poly(ADP-ribose) polymerase 1; RIP1: Receptor-interacting protein kinase 1; TH: Total homogenate.